MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET 2022-2028

Description

MARKET OUTLOOK

CRI’s report suggests that the Middle East and Africa companion diagnostics market is estimated to progress at a compound annual growth rate of 12.53% during the forecast years 2022-2028. Israel, South Africa, the UAE, Saudi Arabia, Turkey, and Rest of Middle East & Africa are studied in the given region.
Over the years, precision medicine has gained significant traction in the United Arab Emirates. In this regard, the government has restructured the reimbursement and pricing systems to gain from the potential of drug-diagnostic pairings. As a result, several companies have revised their strategies to create value for stakeholders, including patients, policymakers, and physicians. Therefore, such efforts to increase the adoption of precision medicine are expected to create lucrative opportunities for the companion diagnostics market.
On the other hand, the companion diagnostics market is at a nascent stage in South Africa. This is because professionals are unable to fully ascertain the potential of quick, accurate, and timely therapeutic intervention. Nevertheless, several manufacturers are targeting the market, owing to the rise in cancer cases. In this regard, a new regulatory authority was formed to oversee the sale of drugs and medical devices. These factors are thus expected to open new avenues for the companion diagnostics market in the upcoming years.

COMPETITIVE OUTLOOK

Major firms in the companion diagnostics market consist of Abbott Laboratories, Illumina Inc, Agilent, Qiagen, and Almac Group.

TABLE OF CONTENTS

1. MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET
2.2. KEY INSIGHTS
2.2.1. COMMERCIAL SUCCESS OF PRECISION MEDICINE TREATMENT
2.2.2. ADOPTION OF PREDICTIVE BIOMARKERS
2.2.3. FUSION OF COMPUTER SCIENCE AND BIOLOGY
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. KEY BUYING IMPACT ANALYSIS
2.4.1. COST
2.4.2. AVAILABILITY
2.4.3. SENSITIVITY & SPECIFICITY
2.4.4. EFFICACY
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VENDOR SCORECARD
2.7. INDUSTRY COMPONENTS
2.8. REGULATORY FRAMEWORK
2.9. KEY MARKET STRATEGIES
2.9.1. ACQUISITIONS
2.9.2. PRODUCT LAUNCHES
2.9.3. CONTRACTS & AGREEMENTS
2.10. MARKET DRIVERS
2.10.1. INCREASE IN INCIDENCE OF MEDICATION REACTIONS
2.10.2. INCREASING PREVALENCE OF CANCER CASES AND FATALITIES
2.10.3. RISING PREVALENCE OF PRECISION MEDICINES
2.11. MARKET CHALLENGES
2.11.1. WEAK REIMBURSEMENT FRAMEWORK
2.11.2. COMMON CASES OF LEAKAGE IN ONCOLOGY COMPANION DIAGNOSTICS
2.12. MARKET OPPORTUNITY
2.12.1. ONGOING RESEARCH AND INVESTMENTS IN NEXT GENERATION GENE-SEQUENCING
3. MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY MECHANISM
3.1. IN-SITU HYBRIDIZATION
3.2. POLYMERASE CHAIN REACTION
3.3. IMMUNOHISTOCHEMISTRY
3.4. NEXT GENERATION SEQUENCING
3.5. OTHER MECHANISMS
4. MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY INDICATOR
4.1. ONCOLOGY
4.2. NEUROLOGY
4.3. INFECTIOUS DISEASES
4.4. OTHER INDICATORS
5. MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY CONSUMER
5.1. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
5.2. REFERENCE LABORATORIES
5.3. OTHER CONSUMERS
6. MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY COMMODITY
6.1. ASSAY KITS AND REAGENTS
6.2. SOFTWARE AND SERVICES
7. MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET – COUNTRY OUTLOOK
7.1. UNITED ARAB EMIRATES
7.2. SAUDI ARABIA
7.3. TURKEY
7.4. SOUTH AFRICA
7.5. REST OF MIDDLE EAST & AFRICA
8. COMPETITIVE LANDSCAPE
8.1. ABBOTT LABORATORIES
8.2. ALMAC GROUP
8.3. ARUP LABORATORIES
8.4. BIOCARTIS
8.5. BIOMERIEUX
8.6. DANAHER CORPORATION
8.7. GE HEALTHCARE
8.8. GENOMIC HEALTH
8.9. ILLUMINA INC
8.10. MYRIAD GENETICS
8.11. QIAGEN
8.12. ROCHE DIAGNOSTICS
8.13. SYSMEX CORPORATION
8.14. THERMO FISHER SCIENTIFIC
8.15. AGILENT
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY

LIST OF TABLES

TABLE 1: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF CONTRACTS & AGREEMENTS
TABLE 6: NUMBER OF CANCER PATIENTS IN 2020
TABLE 7: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 8: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 9: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 10: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 11: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: MARKET ATTRACTIVENESS INDEX
FIGURE 2: INDUSTRY COMPONENTS
FIGURE 3: FDA FRAMEWORK
FIGURE 4: CDX LEAKAGE POINTS
FIGURE 5: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2021 & 2028 (IN %)
FIGURE 6: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY IN-SITU HYBRIDIZATION, 2022-2028 (IN $ MILLION)
FIGURE 7: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2028 (IN $ MILLION)
FIGURE 8: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY IMMUNOHISTOCHEMISTRY, 2022-2028 (IN $ MILLION)
FIGURE 9: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2028 (IN $ MILLION)
FIGURE 10: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY OTHER MECHANISMS, 2022-2028 (IN $ MILLION)
FIGURE 11: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2021 & 2028 (IN %)
FIGURE 12: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2028 (IN $ MILLION)
FIGURE 13: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2028 (IN $ MILLION)
FIGURE 14: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2028 (IN $ MILLION)
FIGURE 15: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATORS, 2022-2028 (IN $ MILLION)
FIGURE 16: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2021 & 2028 (IN %)
FIGURE 17: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, 2022-2028 (IN $ MILLION)
FIGURE 18: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2028 (IN $ MILLION)
FIGURE 19: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY OTHER CONSUMERS, 2022-2028 (IN $ MILLION)
FIGURE 20: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2021 & 2028 (IN %)
FIGURE 21: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2028 (IN $ MILLION)
FIGURE 22: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY SOFTWARE AND SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 23: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 24: UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 25: SAUDI ARABIA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 26: TURKEY COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 27: SOUTH AFRICA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 28: REST OF MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)